Henry Waxman is a household name in pharmaceutical circles — during his three decades on Capitol Hill, he helped write the Affordable Care Act and expand Medicaid and the Children’s Health Insurance Program. He sponsored the 1984 Hatch-Waxman Act, which set up the modern infrastructure for bringing generic drugs to market, and chaired the Energy and Commerce Committee, which has jurisdiction over health-related issues, from 2009 to 2011.

Since his retirement from Congress in 2015, Waxman has served as chairman of Waxman Strategies, a lobbying firm that has been active on health issues, especially the 340B drug discount program.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy